Cargando…
γδ T cells in immunotherapies for B-cell malignancies
Despite the advancements in therapy for B cell malignancies and the increase in long–term survival of patients, almost half of them lead to relapse. Combinations of chemotherapy and monoclonal antibodies such as anti-CD20 leads to mixed outcomes. Recent developments in immune cell-based therapies ar...
Autores principales: | Rimailho, Léa, Faria, Carla, Domagala, Marcin, Laurent, Camille, Bezombes, Christine, Poupot, Mary |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10325712/ https://www.ncbi.nlm.nih.gov/pubmed/37426670 http://dx.doi.org/10.3389/fimmu.2023.1200003 |
Ejemplares similares
-
Monitoring Circulating γδ T Cells in Cancer Patients to Optimize γδ T Cell-Based Immunotherapy
por: Oberg, Hans-Heinrich, et al.
Publicado: (2014) -
A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma
por: Decaup, Emilie, et al.
Publicado: (2019) -
A close look at current γδ T-cell immunotherapy
por: Ma, Ling, et al.
Publicado: (2023) -
Cancer Immunotherapy Using γδT Cells: Dealing with Diversity
por: Scheper, Wouter, et al.
Publicado: (2014) -
Current Advances in γδ T Cell-Based Tumor Immunotherapy
por: Lo Presti, Elena, et al.
Publicado: (2017)